Cannabis shows promise in reducing Tourette syndrome tics and urges

This systematic review and meta-analysis examined the effectiveness of cannabis-based medicines (CBMs) in treating Tourette syndrome (TS), a neurological condition characterized by involuntary motor and vocal tics. The researchers analyzed eight peer-reviewed studies involving 306 adult TS patients and found that cannabis-based treatments significantly reduced tic severity. According to the Yale Global Tic Severity Scale (YGTSS), a standard measurement tool, CBMs produced meaningful improvements with a reduction of 13.29 points on this clinical scale, demonstrating real therapeutic potential where traditional antipsychotic medications have limited options.

Beyond tic reduction, the analysis revealed that cannabis-based treatments also reduced premonitory urges—the uncomfortable sensations that often precede tics—with improvements measured on the Premonitory Urge for Tics Scale (PUTS). This dual benefit is significant because managing both the physical tics and the internal sensations driving them addresses the full patient experience. The interaction with the endocannabinoid system appears to be the mechanism behind these improvements, and importantly, CBMs showed better tolerability compared to conventional antipsychotics, which often carry troublesome side effects that can worsen quality of life.

While these results are encouraging, the researchers emphasize that evidence remains limited and call for larger, placebo-controlled clinical trials to confirm these findings and establish optimal dosing protocols. Current research supports cannabis as a promising therapeutic avenue for TS patients who may not respond well to or tolerate standard treatments, offering hope for improved symptom management and quality of life in a condition that has historically been difficult to treat.